The global pharmaceutical company and service partner Inceptua Group and Bendalis GmbH – German manufacturer of generic oncology drugs and special therapeutic agents, announce the signing of an exclusive clinical trial supply agreement for oncology generics.
Through this agreement Inceptua becomes the exclusive distributor of Bendalis’ products for their use in clinical trials worldwide, offering clinical trial sponsors quick access to Brexit-safe oncology standard of care medicines produced within the European Union.
“With this agreement Bendalis and Inceptua join forces to ensure optimal sourcing and supply of medicines for use in oncology clinical trials to our clients. Together, we share a mission to provide uninterrupted access for patients to high quality products through a secure and robust supply chain,” says Alan Raffensperger, CEO, Inceptua Group.
As a part of the agreement, Bendalis will maintain stock of specific products on a consignment basis, offering Inceptua’s clients “on demand” access. Even the most well planned clinical trials may experience supply challenges at some point. Operating a consignment model provides contingency against manufacturing issues, stock-out situations, and mitigation of study delays which would impact both patients and sponsors.
“In the oncology space we experience a growing need and demand for products. We see Inceptua as the ideal partner to handle the distribution and help optimize the clinical trial supply for clients. A consistent and secure supply of products is a critical component in clinical trials, and together we can offer a flexible yet reliable solution, helping clients minimize overage and reduce costs,” says Christian Parvany, CEO, Bendalis.
With over 8,000 industry sponsored oncology studies currently running or soon to start recruitment, the global need for large volumes of essential medicine is clear. Through this agreement Inceptua adds to the broad range of oncology comparators and standard of care medicine it already supplies for clinical trial use with exclusive access to Bendalis’ portfolio of products that are commonly used in chemotherapy. Products include: carboplatin, docetaxel, gemcitabine, paclitaxel, oxaliplatin, vinorelbine, irinotecan, and fluorouracil (5FU).
About Inceptua Group and Bendalis GmbH:
Bendalis is a leading specialty pharmaceutical company focused on developing and promoting generic and niche proprietary oncology products within Germany and various international markets.
The available know-how across the entire portfolio offers the advantage that every customer receives a dedicated, comprehensive service with respect to marketing authorization, production and distribution strategies.
By collaborating with doctors, pharmacists, wholesalers and partners worldwide, Bendalis has a distribution network and access to in-depth information on markets and products. www.bendalis.com
Inceptua is a pharmaceutical company and service partner spanning throughout the product lifecycle – from comparator sourcing for clinical trials, through early access programs to licensing and commercialization for products.
We partner with life science companies of all sizes, drawing on over 20 years of industry experience. Our pharma and biotech offering includes registration and commercialization of products through in-licensing and flexible partnerships. We have leading expertise in strategy and operational implementation of pre-approval access programs making pharmaceutical products under clinical development available for patients and Inceptua’s clinical trial services business offers high quality clinical comparator sourcing and manufacturing services with an agile global supply chain to ensure that products are delivered exactly when needed. Inceptua has global operations with local offices across Europe, USA, and Asia. www.inceptua.com